According to GLOBOCAN data, nearly 31,000 deaths from lung cancer were reported in Indonesia in 2020. The average age of lung cancer patients is around 58, which is significantly younger than in most other countries. This trend reflects the combined impact of younger smoking habits, occupational exposure, and limited access to medical resources.

"When a lung cancer diagnosis suddenly changes your life, you may find yourself searching for more precise and effective treatment options.
At Foshan Fosun Chancheng Hospital, we understand your concerns. As a well-known tertiary general hospital in South China, we have provided personalized lung cancer treatment plans for many Indonesian patients — from accurate diagnosis and minimally invasive surgery to targeted therapy and immunotherapy. Throughout your treatment journey, Indonesian language interpreters and dedicated medical consultants will accompany you every step of the way, ensuring you experience both the warmth of home and the quality of world-class care right here in Foshan.”

Why Do Lung Cancer Patients Choose Us?

(Foshan Fosun Chancheng Hospital Environment)

1. Internationally Certified Lung Cancer Team — Experienced in Treating Indonesian Patients

The treatment of lung cancer requires a comprehensive and multidisciplinary approach, combining surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. The choice of treatment depends on the patient’s overall health, tumor pathology and cytology, disease stage, and progression trend — with the goal of achieving the best possible tumor control, higher cure rates, and improved quality of life.

To achieve this, Foshan Fosun Chancheng Hospital has established a Multidisciplinary Team (MDT) for lung cancer, led by internationally recognized experts:

Dr. Yang Jun — North American CyberKnife Quality Control Standard Developer With over 20 years of experience in the United States, Dr. Yang studied under world-renowned radiation oncology masters Prof. Luther W. Brady and Prof. Wu Xiaodong.

Dr. Wang Enmin — Chief Radiosurgery Specialist, Center for Precision Oncology

A leading expert in CyberKnife radiotherapy for lung cancer and chief editor of China’s most authoritative CyberKnife monograph.

Dr. Ye Gang — Chief Medical Oncologist

Practiced for many years in the U.S. with extensive experience in clinical treatment and research. Dr. Ye specializes in various cancers and hematological diseases, particularly lung cancer, breast cancer, liver cancer, lymphoma, and multiple myeloma.

Dr. Song Changshan — Chief Thoracic Surgeon

With 30 years of surgical experience, Dr. Song excels in minimally invasive thoracic surgery for esophageal and lung cancers, and in comprehensive management of chest tumors.

Prof. Li Guidong — Renowned Traditional Chinese Medicine (TCM) Practitioner

  A third-generation successor of the Qingshan Medical School of Guizhou, and a graduate of Beijing University of Chinese Medicine, Prof. Li focuses on oncology and has developed a unique TCM system centered on “strengthening vital qi and detoxifying” to support cancer care.

Full Indonesian Language Support: All consultations, treatment explanations, and rehabilitation guidance are provided with professional Indonesian interpreters, ensuring that no detail is lost in translation.

Most members of our team have received advanced training at leading medical institutions in Singapore, the United States, and Europe. They are well-versed in the characteristics of lung cancer among Southeast Asian populations (including Indonesia), such as the high proportion of lung adenocarcinoma and the higher EGFR mutation rate. The team is particularly experienced in providing comprehensive treatment for advanced and complex lung cancers, including those complicated by pleural effusion or brain metastasis.

All core physicians are fluent in English, and every patient is supported by a full-time Indonesian medical interpreter — ensuring smooth, accurate communication from initial consultation to treatment planning and medication guidance, with zero language barriers.

2. Cutting-Edge Precision Diagnostics and Treatment Technology for More Effective Therapy with Fewer Side Effects

Precision Diagnostics: Equipped with PET-CT, 3.0T MRI, and a genetic testing platform covering common mutations in Indonesian patients (such as EGFR, ALK, and ROS1), we provide accurate pathology and genetic reports within 24–48 hours to guide targeted therapy.

3. Advanced Treatment Modalities

Minimally Invasive Surgery: Using thoracoscopic and Da Vinci robotic-assisted procedures, these surgeries are less traumatic and allow faster recovery, making them especially suitable for elderly or frail patients.

Targeted Therapy: Includes commonly used drugs for Indonesian patients, precisely matched to genetic testing results, with significantly fewer side effects than traditional chemotherapy.

Immunotherapy: PD-1/PD-L1 inhibitors provide potential long-term survival for patients with advanced lung cancer lacking actionable mutations.

Precision Radiotherapy: CyberKnife M6 (non-invasive, no bleeding, no anesthesia, uses high-energy beams to precisely target tumors) and Gamma Knife therapy deliver accurate irradiation for locally advanced or metastatic lesions while protecting surrounding healthy tissues.

CyberKnife is an advanced stereotactic radiotherapy system that, guided by high-precision imaging and robotic arm control, focuses high-energy beams precisely on tumor lesions. This “non-invasive ablation” approach is widely used in lung cancer treatment, particularly for patients who cannot or prefer not to undergo surgery.

The following provides a brief overview of indications and advantages:

Indications and Suitable Scenarios for Lung Cancer

1. Early-stage Non-Small Cell Lung Cancer (NSCLC)

For early-stage patients who cannot tolerate surgery due to advanced age, poor cardiopulmonary function, or comorbidities, CyberKnife can serve as a curative treatment option, achieving local control rates comparable to surgery.

2. Metastatic Lesions in Advanced Lung Cancer

For oligometastases in the lungs (few and small metastatic tumors) or extrathoracic metastases (e.g., brain or bone), CyberKnife can precisely ablate metastatic lesions, alleviate symptoms, and extend survival.

3. Postoperative Residual or Recurrent Lesions

For patients with residual tumor after surgery or local recurrence where repeat surgery is not feasible, CyberKnife provides targeted treatment.

Advantages of CyberKnife for Lung Cancer

- High Precision: Real-time imaging tracking (e.g., respiratory synchronization) minimizes errors caused by tumor movement during breathing, focusing radiation on the tumor while sparing surrounding normal lung tissue, heart, and esophagus.

 - Non-Invasive: No surgery is required, avoiding surgical trauma and postoperative complications, suitable for patients with frail physical condition.

 - Short Treatment Course: Conventional radiotherapy usually requires 30–40 sessions, whereas CyberKnife typically completes treatment in 3–5 sessions (30–60 minutes per session), improving patient compliance.

 - Well-Tolerated: Most patients experience minimal discomfort during treatment, with little impact on daily life.

Precautions

CyberKnife is not suitable for all lung cancer patients. Treatment suitability should be assessed by a multidisciplinary team (radiation oncology, thoracic surgery, medical oncology, etc.) based on tumor size, location, stage, and patient condition. Regular follow-up (e.g., CT scans, tumor markers) is necessary to monitor treatment response and side effects.

In conclusion, CyberKnife offers lung cancer patients a precise, minimally invasive treatment option, but suitability must be determined on an individual basis under the guidance of a physician.

4. Transparent and Reasonable Costs, Reducing Financial Burden

 -Clear estimates of treatment costs are provided (e.g., minimally invasive surgery, targeted therapy courses, hospitalization), typically only one-third to one-half of the cost in Western countries.

 - Multiple payment options are supported (including Indonesian Rupiah and international credit cards), and assistance is offered for processing international medical insurance claims.

5. Post-Treatment Follow-Up and Emotional Support

Regular monitoring: Ongoing follow-up helps track recovery and detect recurrence early.

Post-treatment support: Fosun Health International offers psychological counseling and support groups to help patients cope with stress, anxiety, and depression, connecting them with others who have had similar experiences for emotional support.

By implementing these strategies, healthcare providers can significantly improve survival rates for lung cancer patients and enhance long-term treatment outcomes.

Fosun Health is dedicated to tackling the most challenging medical conditions while providing meticulous care for every patient.

Free Consultation Hotline: +8801817833123 / +8801914575388

Patient Story case 1:

A 65-year-old male patient was diagnosed with esophageal cancer that had metastasized to the lungs. Due to his underlying health conditions, he declined surgical treatment.

After a thorough evaluation, Director Lu recommended CyberKnife stereotactic body radiotherapy (SBRT) as an alternative. For patients who are unable or unwilling to undergo surgery, CyberKnife offers a non-invasive option that can achieve tumor control comparable to surgery by delivering high-dose, precisely targeted radiation to lung metastases.

This treatment does not impair lung function and allows patients to maintain their normal daily activities and social life. The procedure is relatively simple — the patient lies still on the treatment couch while the CyberKnife system automatically tracks the tumor in real time, compensating for any movement caused by breathing to ensure accurate radiation delivery.

The patient underwent one treatment course, receiving 11 Gy per session for a total of five sessions (11 Gy × 5 fractions).

 - CyberKnife Care Plan

 - Prescription dose: 11 Gy × 5F

 - Prescription isodose line: 63%

Radiation Therapy Plan:

After just five treatment sessions, the patient showed significant clinical improvement. A follow-up one month after radiotherapy revealed that the original lung lesions had completely disappeared.

Patient Case 2:

Mr. Li (pseudonym), a 71-year-old man, underwent a chest CT scan due to a persistent cough and was diagnosed with a right lung tumor. PET-CT further revealed central-type lung cancer in the right upper lobe, with bilateral hilar and mediastinal metastases. Pathological examination confirmed non–small cell lung cancer (NSCLC).

After a thorough review of Mr. Li’s medical records, Prof. Wang provided a professional and encouraging assessment: he was confident in treating this type of central lung cancer and predicted, based on past clinical experience, that Mr. Li could live at least another five years with appropriate treatment. This prognosis immediately restored confidence and hope to Mr. Li's family.

After carefully weighing the options, Mr. Li decided to proceed with the CyberKnife treatment plan. Prof. Wang designed a comprehensive treatment strategy, starting with large-field irradiation to cover the main tumor area, followed by focused, high-precision irradiation on the residual lesion. During the CyberKnife treatment, he was also prescribed oral targeted therapy drugs, to enhance the overall effect.

The CyberKnife treatment went smoothly, and Mr. Li experienced minimal side effects. Shortly afterward, he developed a temporary worsening of his cough, which quickly resolved with a combination of steroid and antibiotic therapy. After returning home, he continued targeted therapy for about one month, but due to severe side effects, he discontinued it and switched to traditional Chinese medicine for ongoing care.

2019 CyberKnife Treatment Plan:

Both the right lung tumor and metastatic lymph nodes were treated with CyberKnife — initially with five large irradiation beams, followed by four smaller, focused beams. After treatment, Mr. Li experienced only mild coughing.

June 2021 Follow-up:

A follow-up PET-CT scan revealed that the irregular nodule near the right upper hilum had become blurred, surrounded by dense, fibrotic streaks clearly visible on imaging, with extremely low metabolic activity. These findings indicated that the tumor was completely necrotic — and the lymph node metastases had also disappeared entirely.

Patient Case 3:

Patient: Female, 72 years old

Diagnosis: Non–Small Cell Lung Cancer (NSCLC)

The patient had a history of smoking and chronic obstructive pulmonary disease (COPD). She was initially diagnosed with a right upper lobe (RUL) lung lesion, which was PET-positive. Four years ago, the lesion measured 1 cm in diameter and showed no metabolic activity, so no intervention was performed at that time.

However, she later developed severe shortness of breath and coughing. A repeat chest CT revealed that the lesion had enlarged to 1.5 × 1.2 cm. A biopsy confirmed non–small cell lung cancer, and she was diagnosed with Stage IA NSCLC (T1N0M0).

CyberKnife Treatment Plan Parameters

 - Tumor volume: 3.6 cm³

 - Prescription dose: 54 Gy / 3 fractions

 - Target coverage: 100%

 - Tracking system: Xsight Lung Synchrony (no fiducial markers required)

 - Algorithm: Monte Carlo algorithm

 - Collimator size:*20–30 mm

 - Number of beams: 148

 - Prescription isodose line: 75%

Results and Follow-up

At 11 months post-treatment, PET-CT imaging showed no evidence of active disease, with only residual scarring visible. PET results were negative for metabolic activity. The patient remained in good overall condition, with no reported adverse complications following CyberKnife treatment.